Evidence map›Paper›PMID 26180082›Full record

ArticleNeuro-oncology2016

Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.

Qing Ouyang, Gang Chen, Ji Zhou, Lei Li, Zhen Dong, Rui Yang, Lunshan Xu, Hongjuan Cui, Minhui Xu, Liang Yi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides.International journal of molecular sciences · 2024
    Review
  6. International journal of molecular sciences · 2024
    Article
  7. Review
  8. Article
  9. Role of microRNA-494 in tumor progression.American journal of translational research · 2023
    Review
  10. Review
  11. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.Laboratory investigation; a journal of technical methods and pathology · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Qing OuyangDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Gang ChenDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Ji ZhouDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Lei LiDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Zhen DongDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Rui YangDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Lunshan XuDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Hongjuan CuiDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Minhui XuDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Liang YiDepartment of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, China (O.Q., Z.J., X.L., X.M., Y.L.); Biomedical Analysis Center, Third Military Medical University, Chongqing, China (C.G.); State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China (D.Z., Y.R., C.H.); State Key Laboratory of Trauma, Burns and Combined Injury, Department one, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China (L.L.).
Army Medical University · CNDaping Hospital · CNState Key Laboratory of Silkworm Genomic BiologySouthwest University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurotensin (NTS) and its primary receptor NTSR1 are implicated in cancer progression. Aberrant expression of NTS/NTSR1 contributes to the proliferation of glioblastoma cells; however, the mechanism is not fully understood.

methodsMicroarray and real-time PCR were performed to identify the NTS-regulated micro (mi)RNAs. The targets of the miRNAs were identified by luciferase assays and immunoblot analysis. The c-Myc binding sites in the miR-29b-1 and cyclin-dependent kinase (CDK)4 promoters were identified through chromatin immunoprecipitation assay. Cell proliferation was evaluated by Cell Counting Kit-8 assay and flow cytometry analysis. An orthotopic xenograft model demonstrated the role of NTS/NTSR1 and miRNAs in glioblastoma growth in vivo.

resultsPharmacological inhibition or small interfering NTSR1 treatment blocked glioblastoma cell cycle progression in the G1 phase with a concomitantly decreased expression of CDK6, CDK4, and c-Myc. Knockdown of NTSR1 increased the expression of miR-29b-1 and miR-129-3p, which were responsible for the decreased CDK6 expression. NTS/NTSR1 signaling activated the transcription factor c-Myc in U87 cells, leading to increased CDK4 expression and repressed miR-29b-1 expression. Knockdown of NTSR1 decreased the glioblastoma growth in vivo and significantly prolonged the survival time of the tumor-bearing mice, an effect that can be largely reversed by antagomir.

conclusionsOur study showed a novel regulatory mechanism of NTS/NTSR1, an upstream signaling of miRNAs and c-Myc, in glioblastoma progression. The inhibition of the NTSR1 function or the upregulation of miR-29b-1 and miR-129-3p expression impaired glioma cell proliferation. These results suggested that the NTS/NTSR1/c-Myc/miRNA axis may be a potential therapeutic target for glioblastoma therapy.

Indexed as

AnimalsApoptosisBlotting, WesternCell CycleCell ProliferationChromatin ImmunoprecipitationGlioblastomaHumansMiceMice, Inbred NODMice, SCIDMicroRNAsNeurotensinProto-Oncogene Proteins c-mycReal-Time Polymerase Chain ReactionReceptors, NeurotensinMicroRNAsMirn129 microRNA, humanMIRN29a microRNA, humanNeurotensinneurotensin type 1 receptorProto-Oncogene Proteins c-mycReceptors, NeurotensinRNA, MessengerRNA, Small Interferingcell cycleglioblastomamiRNAsneurotensinsignal transduction

Identifiers

PMID26180082
PMCPMC4724174
OpenAlexW2304601051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.